ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2019) 63 GP203 | DOI: 10.1530/endoabs.63.GP203

Effects of cardiovascular function of SGLT-2 inhibitos versus DPP-4 inhibitors in type 2 diabetes with coronary artery disease

Chong Hwa Kim1, Su Jin Jung1, Ji Oh Mok2, Ki Young Lee3 & Sung Rae Kim4


1Division of Endocrinology and Metabolism, Department of Internal Medicine, Sejong General Hospital, Bucheon, Republic of Korea; 2Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea; 3Division of Endocrinology and Metabolism, Department of Internal Medicine, Gachon University Gil Hospital, Incheon, Incheon, Republic of Korea; 4Division of Endocrinology and Metabolism, Department of Internal Medicine, The Catholic University of Korea, Bucheon, Republic of Korea.


Objective: Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium – glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes(T2D) at high CV risk. SGLT2-i should be considered as a valuable therapy in T2D with established atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF). We analyzed the effects of cardiovascular function of SGLT 2 inhibitors in T2D with ASCVD or HF compared with dipeptidyl peptidase-4(DPP-4) inhibitors.

Methods: This is a retrospective, observational study, data from 89 patients with established ASCVD or HF 6 months of the SGLT-2 inhibitors and DPP-4 inhibitors therapy were analyzed, visited medical center from January 2018 to June 2018. We had divided into two groups: one group was SGLT-2 inhibitors and the other was DPP-4 inhibitors and check echocardiography and pro BNP.

Results: A total of 89 patients with T2D were identified as group of SGLT2 inhibitor (n=41) or a DPP-4 inhibitor (n=48). In SGLT2 inhibitors,mean baseline age was 59 years, duration of diabetes 10 years, HbA1C 7.8%, eGFR 81 ml/min per 1.73 m2 and body mass index (BMI) 26 kg/m2. In DPP4 inhibitors,mean baseline age was 65 years, duration of diabetes 13 years, HbA1C 7.6%, eGFR 67 ml/min per 1.73 m2 and body mass index (BMI) 26 kg/m2. The mean follow-up time was 2 years, with a total of 89 patient-years. SGLT2 inhibitors had improvement of left ventricular ejection fraction (+2% vs −2.7%), E/E’ (3/40% vs 5/21%)and pro BNP (−374 pg/ml vs +735 pg/ml) compared with DPP-4 inhibitors.

Conclusion: SGLT-2 inhibitors improved LV systol, diastolic function and proBNP compared with DPP-4 inhibitors in type 2 diabetes with coronary artery disease.

Article tools

My recent searches

No recent searches.